979 Impact of Concomitant Immunomodulator Treatment on Efficacy and Safety of Anti-TNF Therapy in Crohn's Disease: A Meta-Analysis of Placebo Controlled Trials With Individual Patient-Level Data
Jennifer Jones(Dalhousie University), Corey A. Siegel(Dartmouth–Hitchcock Medical Center), Divine Tanyingoh(University of Calgary), Fernando Velayos(Kaiser Permanente San Francisco Medical Center), Shane Devlin, Gilaad G. Kaplan(University of Calgary), Peter M. Irving(Guy's and St Thomas' NHS Foundation Trust), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Leonard Baidoo(University of Pittsburgh Medical Center), Gil Melmed, Adam S. Cheifetz(Beth Israel Deaconess Medical Center), Brian Bressler(University of British Columbia), Miles Sparrow(Alfred Health), Patricia Kozuch(Thomas Jefferson University), Laura H. Raffals, Jean‐Frédéric Colombel(Mount Sinai Hospital)
Cited by 19
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k